Related references
Note: Only part of the references are listed.Phase II trial of weekly nab (nanoparticle albumin-bound)-paclitaxel (nab-paclitaxel) (Abraxane®) in combination with gemcitabine in patients with metastatic breast cancer (N0531)
V. Roy et al.
ANNALS OF ONCOLOGY (2009)
Phase I and Pharmacokinetic Study of Pegylated Liposomal CKD-602 in Patients with Advanced Malignancies
William C. Zamboni et al.
CLINICAL CANCER RESEARCH (2009)
Pharmacokinetic Study of Pegylated Liposomal CKD-602 (S-CKD602) in Patients With Advanced Malignancies
W. C. Zamboni et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2009)
Comprehensive Pharmacogenetic Analysis of Irinotecan Neutropenia and Pharmacokinetics
Federico Innocenti et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Recruitment of dendritic cells in human liver with metastases
M. Gulubova et al.
CLINICAL & EXPERIMENTAL METASTASIS (2008)
Concept and clinical evaluation of carrier-mediated anticancer agents
William C. Zamboni
ONCOLOGIST (2008)
An open-label study to evaluate dose and cycle dependence of the pharmacokinetics of pegylated liposomal doxorubicin
Alberto Gabizon et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2008)
Belotecan, new camptothecin analogue, is active in patients with small-cell lung cancer: results of a multicenter early phase II study
D. H. Lee et al.
ANNALS OF ONCOLOGY (2008)
Plasma, tumor, and tissue disposition of STEALTH liposomal CKD-602 (S-CKD602) and nonliposomal CKD-602 in mice bearing A375 human melanoma xenografts
William C. Zamboni et al.
CLINICAL CANCER RESEARCH (2007)
Phase I and pharmacokinetic study of a low-clearance, unilamellar liposomal formulation of lurtotecan, a topoisomerase 1 inhibitor, in patients with advanced leukemia
FJ Giles et al.
CANCER (2004)
Drug delivery systems: Entering the mainstream
TM Allen et al.
SCIENCE (2004)
A phase 1 study of OSI-211 given as an intravenous infusion days 1, 2, and 3 every three weeks in patients with solid cancers
K Gelmon et al.
INVESTIGATIONAL NEW DRUGS (2004)
Phenotypic and functional changes of circulating monocytes and polymorphonuclear leucocytes from elderly persons
M De Martinis et al.
IMMUNOLOGY AND CELL BIOLOGY (2004)
Liposomal anthracycline treatment for ovarian cancer
M Markman et al.
SEMINARS IN ONCOLOGY (2004)
Use of liposomal anthracyclines in Kaposi's sarcoma
SE Krown et al.
SEMINARS IN ONCOLOGY (2004)
Pharmacokinetics of pegylated liposomal doxorubicin - Review of animal and human studies
A Gabizon et al.
CLINICAL PHARMACOKINETICS (2003)
Dose dependency of pharmacokinetics and therapeutic efficacy of pegylated liposomal doxorubicin (DOXIL) in murine models
A Gabizon et al.
JOURNAL OF DRUG TARGETING (2002)
Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review
H Maeda et al.
JOURNAL OF CONTROLLED RELEASE (2000)
Share Paper
